The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma

The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.

The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.

Inclusion Criteria:

• Diagnosed with sq-NSCLC;
• Receiving immunotherapy combined with or without chemotherapy as first-line treatment;
• ≥ 18 years and ≤ 80 years old;
• No previous treatment in the lungs or any other organ.

Exclusion Criteria:

• History of cancer treatment;
• History of other malignant tumors;
• Irregular treatment or poor compliance;
• Incomplete clinical information or lost to follow-up.